Specialty pharmacy prior authorization update - Certain drugs for treatment of ocular conditions continue to require prior authorization

In the March 2021 issue of Provider News, we advised we would no longer require prior authorization for the following drugs used to treat ocular conditions effective May 1, 2021. Please be advised that prior authorization will continue to be required for these drugs. We apologize for any inconvenience. 

 

Drug	Code	Code description
*Avastin	C9257, J9035	intravitreal bevacizumab
*Mvasi	Q5107	bevacizumab-awwb
*Zirabev	Q5118	bevacizumab-bvzr

*Non-oncology use is managed by Anthem’s medical specialty drug review team.

 

1160-0521-PN-CNT